BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turco L, Garcia-Tsao G, Magnani I, Bianchini M, Costetti M, Caporali C, Colopi S, Simonini E, De Maria N, Banchelli F, Rossi R, Villa E, Schepis F. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. J Hepatol. 2018;68:949-958. [PMID: 29331339 DOI: 10.1016/j.jhep.2017.12.027] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 E Frenk N, Bochnakova T, Ganguli S, Mercaldo N, S Allegretti A, S Pratt D, Yamada K. Small-diameter TIPS combined with splenic artery embolization in the management of refractory ascites in cirrhotic patients. Diagn Interv Radiol 2021;27:232-7. [PMID: 33517259 DOI: 10.5152/dir.2021.19530] [Reference Citation Analysis]
2 Turco L, Garcia-tsao G, Rossi R, Villa E, Schepis F. Reply to: “It takes two “eyes” to see in depth”. Journal of Hepatology 2019;70:791-3. [DOI: 10.1016/j.jhep.2018.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Zanetto A, Shalaby S, Feltracco P, Gambato M, Germani G, Russo FP, Burra P, Senzolo M. Recent Advances in the Management of Acute Variceal Hemorrhage. J Clin Med 2021;10:3818. [PMID: 34501265 DOI: 10.3390/jcm10173818] [Reference Citation Analysis]
4 Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link? World J Clin Cases 2021;9:9320-32. [PMID: 34877269 DOI: 10.12998/wjcc.v9.i31.9320] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mechelinck M, Hartmann B, Hamada S, Becker M, Andert A, Ulmer TF, Neumann UP, Wirtz TH, Koch A, Trautwein C, Roehl AB, Rossaint R, Hein M. Global Longitudinal Strain at Rest as an Independent Predictor of Mortality in Liver Transplant Candidates: A Retrospective Clinical Study. J Clin Med 2020;9:E2616. [PMID: 32806645 DOI: 10.3390/jcm9082616] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Alvarado-Tapias E, Vilades D, Brujats A, Villanueva C. Reply to: "Non-selective beta blockers and mortality in decompensated cirrhosis: Is cirrhotic cardiomyopathy the missing link?". J Hepatol 2021;75:993-4. [PMID: 34224780 DOI: 10.1016/j.jhep.2021.06.026] [Reference Citation Analysis]
7 Kaur H, Premkumar M. Diagnosis and Management of Cirrhotic Cardiomyopathy. Journal of Clinical and Experimental Hepatology 2022;12:186-99. [DOI: 10.1016/j.jceh.2021.08.016] [Reference Citation Analysis]
8 Abraldes JG, Trebicka J, Chalasani N, D’amico G, Rockey DC, Shah VH, Bosch J, Garcia-tsao G. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension: Hepatology. Hepatology 2019;69:1287-99. [DOI: 10.1002/hep.30314] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
9 Rabiee A, Garcia‐tsao G, Tapper EB. Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How? Clinical Liver Disease. [DOI: 10.1002/cld.1182] [Reference Citation Analysis]
10 Costa D, Simbrunner B, Reiberger T. Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease". J Hepatol 2021;74:1000-1. [PMID: 33497763 DOI: 10.1016/j.jhep.2021.01.026] [Reference Citation Analysis]
11 Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol 2020;73:829-41. [PMID: 32298768 DOI: 10.1016/j.jhep.2020.03.048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
12 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 López-Sánchez GN, Dóminguez-Pérez M, Uribe M, Nuño-Lámbarri N. The fibrogenic process and the unleashing of acute-on-chronic liver failure. Clin Mol Hepatol 2020;26:7-15. [PMID: 31195778 DOI: 10.3350/cmh.2019.0011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Shiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ; IDN-6556-14 Investigators(‡). Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol 2020;72:885-95. [PMID: 31870950 DOI: 10.1016/j.jhep.2019.12.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
15 Turco L, Garcia-Tsao G. Portal Hypertension: Pathogenesis and Diagnosis. Clin Liver Dis. 2019;23:573-587. [PMID: 31563212 DOI: 10.1016/j.cld.2019.07.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
16 Téllez L, Ibáñez-Samaniego L, Pérez Del Villar C, Yotti R, Martínez J, Carrión L, Rodríguez de Santiago E, Rivera M, González-Mansilla A, Pastor Ó, Bermejo J, Bañares R, Albillos A. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol 2020;73:1404-14. [PMID: 32446716 DOI: 10.1016/j.jhep.2020.05.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
17 Starlinger P, Ahn JC, Mullan A, Gyoeri GP, Pereyra D, Alva-Ruiz R, Hackl H, Reiberger T, Trauner M, Santol J, Simbrunner B, Mandorfer M, Berlakovich G, Kamath PS, Heimbach J. The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality. Hepatology 2021. [PMID: 33786862 DOI: 10.1002/hep.31838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Garcia-tsao G. Long-term albumin in cirrhosis: is it the ANSWER? The Lancet 2018;391:2391-2. [DOI: 10.1016/s0140-6736(18)30948-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
19 Mehtani R, Roy A, Verma N, Premkumar M, Singh V. Beta-blockers in refractory ascites - is it truly the end of the road? J Hepatol 2020;73:1290-1. [PMID: 32861511 DOI: 10.1016/j.jhep.2020.06.035] [Reference Citation Analysis]
20 Giannelli V, Roux O, Laouénan C, Manchon P, Ausloos F, Bachelet D, Rautou PE, Weiss E, Moreau R, Mebazaa A, Cohen-Solal A, Durand F, Francoz C. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol 2020;72:463-71. [PMID: 31622697 DOI: 10.1016/j.jhep.2019.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
21 Reichert MC, Ripoll C, Casper M, Greinert R, Vandieken E, Grünhage F, Appenrodt B, Zipprich A, Lammert F. Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis. Clin Transl Gastroenterol 2019;10:e00002. [PMID: 30702490 DOI: 10.14309/ctg.0000000000000002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Yu J, Shi X, Ma J, Chen R, Dong S, Lu S, Wu J, Yan C, Wu J, Zheng S, Li L, Xu X, Cao H. C-Reactive Protein Is an Independent Predictor of 30-Day Bacterial Infection Post-Liver Transplantation. Biomolecules 2021;11:1195. [PMID: 34439862 DOI: 10.3390/biom11081195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Thevenot T, Mouhat B, Cervoni J, Chopard R. The dual role of non‐selective beta‐blockers in cirrhotic patients: How do we know when Dr Jekyll turns into Mr Hyde? Liver Int 2021;41:1166-7. [DOI: 10.1111/liv.14770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Alvarado E, Garcia-guix M, Mirabet S, Villanueva C. The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis. Journal of Hepatology 2018;69:746-7. [DOI: 10.1016/j.jhep.2018.04.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
25 Zanetto A, Garcia-Tsao G. Management of acute variceal hemorrhage. F1000Res 2019;8:F1000 Faculty Rev-966. [PMID: 31281637 DOI: 10.12688/f1000research.18807.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
26 Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, Schwabl P, Scheiner B, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.J Hepatol. 2021;74:819-828. [PMID: 33075344 DOI: 10.1016/j.jhep.2020.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
27 Coenraad M, Porcher R, Bendtsen F. Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: It takes three to tango. Journal of Hepatology 2018;68:887-9. [DOI: 10.1016/j.jhep.2018.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
28 Italian Association for the Study of the Liver (AISF). Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2021;53:1089-104. [PMID: 34321192 DOI: 10.1016/j.dld.2021.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 D’amico G, Perricone G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter? Curr Hepatology Rep 2019;18:144-56. [DOI: 10.1007/s11901-019-00473-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Monteiro S, Grandt J, Uschner FE, Kimer N, Madsen JL, Schierwagen R, Klein S, Welsch C, Schäfer L, Jansen C, Claria J, Alcaraz-Quiles J, Arroyo V, Moreau R, Fernandez J, Bendtsen F, Mehta G, Gluud LL, Møller S, Praktiknjo M, Trebicka J. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. Gut 2021;70:379-87. [PMID: 32241903 DOI: 10.1136/gutjnl-2019-320170] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
31 Praktiknjo M, Monteiro S, Grandt J, Kimer N, Madsen JL, Werge MP, William P, Brol MJ, Turco L, Schierwagen R, Chang J, Klein S, Uschner FE, Welsch C, Moreau R, Schepis F, Bendtsen F, Gluud LL, Møller S, Trebicka J. Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. Liver Int 2020;40:1457-66. [PMID: 32162397 DOI: 10.1111/liv.14433] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
32 Turco L, de Raucourt E, Valla DC, Villa E. Anticoagulation in the cirrhotic patient. JHEP Rep 2019;1:227-39. [PMID: 32039373 DOI: 10.1016/j.jhepr.2019.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
33 Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol 2021;75 Suppl 1:S49-66. [PMID: 34039492 DOI: 10.1016/j.jhep.2021.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Biselli M, Gramenzi A, Lenzi B, Dall'Agata M, Pierro ML, Perricone G, Tonon M, Bellettato L, D'Amico G, Angeli P, Boffelli S, Bonavita ME, Domenicali M, Caraceni P, Bernardi M, Trevisani F. Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding. Clin Gastroenterol Hepatol 2019;17:1388-1397.e1. [PMID: 30557740 DOI: 10.1016/j.cgh.2018.12.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 La Mura V, Garcia‐guix M, Berzigotti A, Abraldes JG, García‐pagán JC, Villanueva C, Bosch J. A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. Hepatology 2020;72:1353-65. [DOI: 10.1002/hep.31125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, Bauer DJM, Paternostro R, Schwabl P, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut 2021;70:1758-67. [PMID: 33199442 DOI: 10.1136/gutjnl-2020-322712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
37 Wiese S, Hove JD, Mo S, Mygind ND, Tønnesen J, Petersen CL, Clemmesen JO, Goetze JP, Bendtsen F, Møller S. Cardiac dysfunction in cirrhosis: a 2-yr longitudinal follow-up study using advanced cardiac imaging. Am J Physiol Gastrointest Liver Physiol 2019;317:G253-63. [PMID: 31216181 DOI: 10.1152/ajpgi.00402.2018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
38 Garcia-Tsao G. Prophylactic Antibiotics in Cirrhosis: Are They Promoting or Preventing Infections? Clin Liver Dis (Hoboken) 2019;14:98-102. [PMID: 31632658 DOI: 10.1002/cld.819] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Garcia-Tsao G. Acute-on-Chronic Liver Failure: An Old Entity in Search of Clarity. Hepatol Commun 2018;2:1421-4. [PMID: 30556031 DOI: 10.1002/hep4.1287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
40 Turco L, Villanueva C, La Mura V, García-pagán JC, Reiberger T, Genescà J, Groszmann RJ, Sharma BC, Merkel C, Bureau C, Alvarado E, Abraldes JG, Albillos A, Bañares R, Peck-radosavljevic M, Augustin S, Sarin SK, Bosch J, García-tsao G. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology 2020;18:313-327.e6. [DOI: 10.1016/j.cgh.2019.05.050] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
41 O'Brien A. Con: The Unclear Benefit of Albumin. Liver Transpl 2019;25:135-9. [PMID: 30447173 DOI: 10.1002/lt.25384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
42 Rossi R, Talarico M, Schepis F, Coppi F, Sgura FA, Monopoli DE, Minici R, Boriani G. Effects of sildenafil on right ventricle remodelling in Portopulmonary hypertension. Pulm Pharmacol Ther 2021;70:102071. [PMID: 34428597 DOI: 10.1016/j.pupt.2021.102071] [Reference Citation Analysis]
43 Tonon M, Piano S, Gambino CG, Romano A, Pilutti C, Incicco S, Brocca A, Sticca A, Bolognesi M, Angeli P. Outcomes and Mortality of Grade 1 Ascites and Recurrent Ascites in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2020;. [PMID: 32272250 DOI: 10.1016/j.cgh.2020.03.065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Møller S, Danielsen KV, Wiese S, Hove JD, Bendtsen F. An update on cirrhotic cardiomyopathy. Expert Rev Gastroenterol Hepatol 2019;13:497-505. [PMID: 30802157 DOI: 10.1080/17474124.2019.1587293] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
45 Owen NE, Alexander GJ, Sen S, Bunclark K, Polwarth G, Pepke-Zaba J, Davenport AP, Morrell NW, Upton PD. Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis. EBioMedicine 2020;56:102794. [PMID: 32454407 DOI: 10.1016/j.ebiom.2020.102794] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
46 Piano S, Angeli P. Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation? Clin Liver Dis 2021;25:357-72. [PMID: 33838855 DOI: 10.1016/j.cld.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Turco L, Schepis F, Villa E. The Role of Anticoagulation in Treating Portal Hypertension. Curr Hepatol Rep 2018;17:200-8. [PMID: 30546994 DOI: 10.1007/s11901-018-0406-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
48 Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, Schepis F, Garcia-Pagan JC, Merli M, Meyer C, Strassburg CP, Pieper CC, Trebicka J. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep 2021;3:100264. [PMID: 34013182 DOI: 10.1016/j.jhepr.2021.100264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
49 Lange CM. Systemic inflammation in hepatorenal syndrome – A target for novel treatment strategies? Liver Int 2019;39:1199-201. [DOI: 10.1111/liv.14057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
50 Balakrishnan M, Falker C, Conley S, Ciarleglio M, Deng Y, Redeker NS, Garcia-Tsao G. Sleep Disturbance Is Associated With the Presence of Portosystemic Collaterals in Patients With Compensated Cirrhosis. Hepatol Commun 2021;5:491-501. [PMID: 33681681 DOI: 10.1002/hep4.1636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 O'brien A, Kamath PS, Trotter J. MACHT – Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list. Journal of Hepatology 2018;69:1217-8. [DOI: 10.1016/j.jhep.2018.09.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
52 Debnath P, Rathi P. Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease. J Hepatol 2021;74:999-1000. [PMID: 33340583 DOI: 10.1016/j.jhep.2020.11.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019; 25(39): 5897-5917 [PMID: 31660028 DOI: 10.3748/wjg.v25.i39.5897] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
54 D'Amico G, Abraldes JG, Rebora P, Valsecchi MG, Garcia-Tsao G. Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. Hepatology 2020;72:1029-42. [PMID: 31837238 DOI: 10.1002/hep.31070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
55 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
56 Balcar L, Semmler G, Pomej K, Simbrunner B, Bauer D, Hartl L, Jachs M, Paternostro R, Bucsics T, Pinter M, Trauner M, Mandorfer M, Reiberger T, Scheiner B. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. United European Gastroenterol J 2021;9:427-37. [PMID: 34050619 DOI: 10.1002/ueg2.12089] [Cited by in F6Publishing: 1] [Reference Citation Analysis]